The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Genetic Modifiers of Systemic Lupus Erythematosus in FcγRIIB−/− Mice
Open accessAbstract
FcγRIIB is a potent lupus susceptibility gene as demonstrated by the observation that mice deficient in this molecule develop spontaneous antinuclear antibodies (ANA) and fatal glomerulonephritis when on the C57BL/6 background. To determine the mechanisms underlying the epistasis displayed by this gene we have constructed hybrids between FcγRIIB−/− and the systemic lupus erythematosus (SLE) modifiers yaa and lpr and the susceptibility locus Sle1. Sle1 and B6.RIIB−/− are both physically and functionally coupled; compound heterozygotes of Sle1 and B6.RIIB−/− develop significant disease, while single heterozygotes display no evidence of autoimmunity or disease, indicating that these genes lie on the same genetic pathway resulting in the loss of tolerance to nuclear antigens. However, the generation of ANA in itself is insufficient to account for the severity of autoimmune disease in this model, as demonstrated by analysis of yaa and lpr hybrids. Thus, B6.RIIB−/−/lpr mice are protected from disease progression, despite equivalent titers of ANA. In contrast, B6.RIIB−/−/yaa mice have significantly enhanced disease despite reduced ANA titers. Yaa modifies the specificity and thus the pathogenicity of the B6. RIIB−/− ANA, by converting them to antinucleolar antibodies. In addition to these known modifier pathways, we have discovered two novel, recessive loci contributed by the C57BL/6 genome that are required for the ANA phenotype, further indicating the epistatic properties of this SLE model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Lander, E. S., Green, P., Abrahamson, J., Barlow, A., Daly, M. J., Lincoln, S. E., & Newburg, L. (1987) · Genomics · doi:10.1016/0888-7543(87)90010-3 · Cited by 6,656
Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results
Lander, E., & Kruglyak, L. (1995) · Nature Genetics · doi:10.1038/ng1195-241 · Cited by 5,239
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“Conversely, the inhibitory Fc � R, Fc � RIIB, prevents inappropriate activation of effector responses; its deletion renders animals hyperresponsive to sub-threshold levels of cytotoxic antibodies and immune complexes (24, 25 ).”
BackgroundNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Ravetch, J. V., & Bolland, S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,657
Self-citationAugmented humoral and anaphylactic responses in FcγRII-deficient mice
Takai, T., Ono, M., Hikida, M., Ohmori, H., & Ravetch, J. V. (1996) · Nature · doi:10.1038/379346a0 · Cited by 826
Self-citationSpontaneous Autoimmune Disease in FcγRIIB-Deficient Mice Results from Strain-Specific Epistasis
Bolland, S., & Ravetch, J. V. (2000) · Immunity · doi:10.1016/s1074-7613(00)00027-3 · Cited by 752
Self-citation
Cited by
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Self-citationPoints of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738
Toll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116
THE NOD MOUSE: A Model of Immune Dysregulation
Anderson, M. S., & Bluestone, J. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115643 · Cited by 1,113
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Self-citationAutoreactive B Cell Responses to RNA-Related Antigens Due to TLR7 Gene Duplication
Pisitkun, P., Deane, J. A., Difilippantonio, M. J., Tarasenko, T., Satterthwaite, A. B., & Bolland, S. (2006) · Science · doi:10.1126/science.1124978 · Cited by 894
Self-citationDeane, J. A., Pisitkun, P., Barrett, R. S., Feigenbaum, L., Town, T., Ward, J. M., Flavell, R. A., & Bolland, S. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.009 · Cited by 636
Self-citationRoles of Fc receptors in autoimmunity
Takai, T. (2002) · Nature Reviews Immunology · doi:10.1038/nri856 · Cited by 626
Fc‐Receptors as Regulators of Immunity
Nimmerjahn, F., & Ravetch, J. V. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96005-8 · Cited by 418
Self-citationMarshak-Rothstein, A., & Rifkin, I. R. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104514 · Cited by 389
A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs
Anthony, R. M., & Ravetch, J. V. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9405-6 · Cited by 318
Self-citationFcγRIIb controls bone marrow plasma cell persistence and apoptosis
Xiang, Z., Cutler, A. J., Brownlie, R. J., Fairfax, K., Lawlor, K. E., Severinson, E., Walker, E. U., Manz, R. A., Tarlinton, D. M., & Smith, K. G. C. (2007) · Nature Immunology · doi:10.1038/ni1440 · Cited by 296
Systemic lupus erythematosus: all roads lead to type I interferons
Pascual, V., Farkas, L., & Banchereau, J. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.09.014 · Cited by 285
Antibody‐mediated modulation of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00910.x · Cited by 285
Self-citationYokogawa, M., Takaishi, M., Nakajima, K., Kamijima, R., Fujimoto, C., Kataoka, S., Terada, Y., & Sano, S. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38298 · Cited by 284
Toll-like Receptor 7-Dependent Loss of B Cell Tolerance in Pathogenic Autoantibody Knockin Mice
Berland, R., Fernandez, L., Kari, E., Han, J.-H., Lomakin, I., Akira, S., Wortis, H. H., Kearney, J. F., Ucci, A. A., & Imanishi-Kari, T. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.014 · Cited by 256
The role and function of Fcγ receptors on myeloid cells
Bournazos, S., Wang, T. T., & Ravetch, J. V. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0045-2016 · Cited by 138
Self-citationRegulation of autoreactive B cell responses to endogenous TLR ligands
Avalos, A. M., Busconi, L., & Marshak-Rothstein, A. (2010) · Autoimmunity · doi:10.3109/08916930903374618 · Cited by 114
Lauwerys, B. R., & Wakeland, E. K. (2005) · Lupus · doi:10.1191/0961203305lu2052oa · Cited by 42
Self-citation
Metadata
- Authors
- Bolland, S., Yim, Y.-S., Tus, K., Wakeland, E. K., & Ravetch, J. V.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-04-29
- Volume
- 195
- Issue
- 9
- Pages
- 1167-1174
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2156418336
- Cited by
- 256
- References
- 37
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.